Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Age: Between 18 - 100 Years
Gender: Male or Female
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required